A Japanese case report links the kidney cancer drug cabozantinib to microthrombi that produced skin necrosis mimicking ...
Combination achieved mOS of 23.8 months in patients with unresectable or metastatic HCCFORT LEE, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Elevar ...
Mab Designs Ltd today announced the publication of a peer-reviewed study of C20, its anti-interleukin-6 trans-signalling antibody, in Communications Biology, a Nature Portfolio journal. The paper, ...
Merck showcases first-time pivotal phase 3 results from oncology pipeline and continued innovative potential of existing portfolio at ESMO 2026: Rahway, New Jersey Wednesday, Octo ...
From Awareness to Adaptive Oncology - AI, Molecular Resistance, and Adaptive Oncology in Breast Cancer / Breast Cancer, ...
A CT-based multimodal radiogenomic model combining tumor imaging, perirenal fat features, and genetic data outperformed ...
Elevar Therapeutics, Inc., a biopharmaceutical company and a majority-owned subsidiary of HLB Co., Ltd. (028300.KQ), announced that it resubmitted a New Drug Application (NDA) to the U.S. Food and ...
Explore the preclinical research catching our eye in October 2026, from AI drug design to small molecules and gene therapy ...
C20 blocks human IL-6 trans-signalling while leaving classic signalling intact.LONDON, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Mab Designs Ltd today announced the publication of a peer-reviewed study of C20 ...
Crescent Biopharma, Inc. announced clinical pipeline momentum, including enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care chemotherapy regimens ...
Pfizer Inc. (NYSE:PFE) has barely rewarded shareholders over the past year. That underperformance has left Pfizer looking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results